ClinVar Miner

Submissions for variant NM_004168.4(SDHA):c.553C>T (p.Gln185Ter)

gnomAD frequency: 0.00001  dbSNP: rs775827529
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000575535 SCV000664453 pathogenic Hereditary cancer-predisposing syndrome 2022-11-01 criteria provided, single submitter clinical testing The p.Q185* pathogenic mutation (also known as c.553C>T), located in coding exon 5 of the SDHA gene, results from a C to T substitution at nucleotide position 553. This changes the amino acid from a glutamine to a stop codon within coding exon 5. In one study, this mutation was detected in tumor and normal tissue of a 31-year-old male patient whose gastrointestinal stromal tumor showed lack of SDHB and SDHA expression (Wagner AJ et al. Mod. Pathol. 2013 Feb;26:289-94). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Invitae RCV000702668 SCV000831531 pathogenic Mitochondrial complex II deficiency, nuclear type 1; Paragangliomas 5 2023-12-06 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Gln185*) in the SDHA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SDHA are known to be pathogenic (PMID: 22974104, 24781757). This variant is present in population databases (rs775827529, gnomAD 0.002%). This premature translational stop signal has been observed in individual(s) with a gastrointestinal stromal tumor (PMID: 22955521). ClinVar contains an entry for this variant (Variation ID: 480771). RNA analysis performed to evaluate the impact of this premature translational stop signal on mRNA splicing indicates it does not significantly alter splicing (Invitae). For these reasons, this variant has been classified as Pathogenic.
Sema4, Sema4 RCV000575535 SCV002527754 pathogenic Hereditary cancer-predisposing syndrome 2022-02-16 criteria provided, single submitter curation
GeneDx RCV003159959 SCV003915015 pathogenic not provided 2022-10-12 criteria provided, single submitter clinical testing Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 22955521, 30877234, 26689913, 29625052)
Baylor Genetics RCV003476321 SCV004200659 pathogenic Dilated cardiomyopathy 1GG 2023-03-21 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV003159959 SCV004562494 pathogenic not provided 2023-09-06 criteria provided, single submitter clinical testing The SDHA c.553C>T; p.Gln185Ter variant (rs775827529) is reported in the literature in at least four individuals affected with either gastrointestinal stromal tumor (GIST), stomach adenocarcinoma, pancreatic cancer or paraganglioma (Ben Aim 2019, Lu 2015, Puccini 2022, Wagner 2013). This variant is also reported in ClinVar (Variation ID: 480771). This variant is only observed on two alleles in the Genome Aggregation Database, indicating it is not a common polymorphism. This variant induces an early termination codon and is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Additionally, several downstream truncating variants have been described in individuals with GIST and are considered pathogenic (Pantaleo 2022). Based on available information, this variant is considered to be pathogenic. References: Ben Aim L et al. Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. J Med Genet. 2019 Aug;56(8):513-520. PMID: 30877234. Lu C et al. Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun. 2015 Dec 22;6:10086. PMID: 26689913. Puccini A et al. Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients. Cancers (Basel). 2022 Sep 13;14(18):4447. PMID: 36139606. Wagner AJ et al. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod Pathol. 2013 Feb;26(2):289-94. PMID: 22955521.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.